- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Natural Investments Trims Stake in AbbVie
Institutional investor reduces holdings in pharmaceutical giant by over a quarter
Apr. 14, 2026 at 12:23pm
Got story updates? Submit your updates here. ›
The complex financial machinery behind pharmaceutical giants like AbbVie is reflected in the shifting investment strategies of major institutional players.North Chicago TodayNatural Investments LLC, a major investment firm, has reduced its stake in AbbVie Inc. (NYSE: ABBV) by 27.1% during the fourth quarter, according to a recent SEC filing. The firm now owns 28,305 shares of the pharmaceutical company's stock, valued at $6.47 million.
Why it matters
AbbVie is one of the largest pharmaceutical companies in the world, with a diverse portfolio of blockbuster drugs. Institutional investor activity in the stock can provide insights into market sentiment and future performance expectations.
The details
According to the SEC filing, Natural Investments sold 10,548 shares of AbbVie during the fourth quarter, reducing its total holdings to 28,305 shares. The firm's investment in AbbVie now represents 1.6% of its overall portfolio, making it the 13th largest position.
- The stake reduction occurred during the fourth quarter of 2025.
- Natural Investments filed the disclosure with the SEC on April 14, 2026.
The players
Natural Investments LLC
A major institutional investment firm that has reduced its stake in pharmaceutical giant AbbVie.
AbbVie Inc.
A global biopharmaceutical company that focuses on discovering, developing and commercializing specialty medicines across multiple therapeutic areas.
The takeaway
This reduction in stake by a major institutional investor could signal a shift in market sentiment around AbbVie, though the company's diverse drug portfolio and strong pipeline continue to make it an attractive long-term investment for many analysts.
